Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...
2h
Barchart on MSNRegeneron Pharmaceuticals Stock: Analyst Estimates & RatingsTarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...
Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
10hon MSN
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making ...
Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results